A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy
- 13 September 2007
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 110 (2), 327-335
- https://doi.org/10.1007/s10549-007-9726-1
Abstract
This study assessed the clinical efficacy of the farnesyltransferase inhibitor, tipifarnib, combined with letrozole in patients with advanced breast cancer and disease progression following antiestrogen therapy.Keywords
This publication has 22 references indexed in Scilit:
- The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progressionin vitroandin vivoMolecular Cancer Therapeutics, 2007
- Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patientsBritish Journal of Clinical Pharmacology, 2006
- Dual Inhibition of mTOR and Estrogen Receptor SignalingIn vitroInduces Cell Death in Models of Breast CancerClinical Cancer Research, 2005
- Serum HER‐2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapyCancer, 2005
- Molecular Changes in Tamoxifen-Resistant Breast Cancer: Relationship Between Estrogen Receptor, HER-2, and p38 Mitogen-Activated Protein KinaseJournal of Clinical Oncology, 2005
- Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt ActivityClinical Cancer Research, 2004
- Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI‐277 on inhibition of MCF‐7 breast cancer cell‐cycle progressionInternational Journal of Cancer, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer.Endocrine-Related Cancer, 1999
- Aberrant function of the Ras signal transduction pathway in human breast cancerBreast Cancer Research and Treatment, 1995